



DEVELOPMENT PROGRAMS - HEMATOLOGY

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab (anti-PD-1)				R/R cHL
				R/R cHL
BGB-10188 +/- Zanubrutinib				B-cell malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy				B-cell malignancies
				R/R CLL/SLL
				R/R MCL
BGB-11417 + Azacitidine +/- Posaconazole				Myeloid malignancies
BGB-11417 + Dexamethasone +/- Carfilzomib				R/R multiple myeloma with t(11;14)
BGB-11417 monotherapy + Zanubrutinib				B-cell malignancies
BGB-16673 (BTK-targeted CDAC)				B-cell malignancies
				B-cell malignancies
Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab				R/R DLBCL
Zandelisib +/- Zanubrutinib or Rituximab*				
Zanubrutinib				R/R DLBCL with CD79B
				Previously treated B-cell malignancies
				B-cell malignancies
				Bioavailability of zanubrutinib tablets vs capsules in healthy volunteers
Zanubrutinib + Lenalidomide +/- Rituximab				R/R DLBCL
Zanubrutinib + Obinutuzumab				R/R FL
Zanubrutinib + Rituximab				1L MCL
				R/R MZL
Zanubrutinib +/- Venetoclax†				1L CLL/SLL

*In collaboration with MEI Pharma.
†This combination is being studied in the third cohort of NCT03336333.

Safety and efficacy have not been established for investigational products and/or uses.

CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PIK3δ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; WM, Waldenström macroglobulinemia.

FOR MORE INFORMATION, CONTACT: MEDICALINFORMATION@BEIGENE.COM

Australia, US

United States

Australia, China

China

Switzerland, US

Worldwide

Japan